Table 2.
Data Overview of Serum and Urine Biomarkers a
| Serum ARGS-aggrecan | Concentration, pmol/mL | Norm | P Value | N (n With Data > LLOQ) |
|---|---|---|---|---|
| Reference group | 0.18 (0.14-0.22) | 1.00 | — | 26 (26) |
| ACL injury group | ||||
| Baseline | 0.27 (0.20-0.36) | 1.50 | <.001 | 147 (146) b |
| 1 y | 0.24 (0.19-0.33) | 1.33 | <.001 | 132 (132) |
| 2 y | 0.22 (0.17-0.28) | 1.22 | .010 | 129 (129) |
| Serum IFN-γ | Concentration, pg/mL | Norm | P Value | N (n With Data > LLOQ) |
| Reference group | 2.01 (0.66-2.71) | 1.00 | — | 16 (11) |
| ACL injury group | ||||
| Baseline | 1.79 (0.66-3.13) | 0.89 | .910 | 148 (93) |
| 1 y | 1.56 (0.66-2.64) | 0.78 | .634 | 132 (73) |
| 2 y | 1.43 (0.66-2.77) | 0.71 | .504 | 129 (69) |
| Serum IL-8 | Concentration, pg/mL | Norm | P Value | N (n With Data > LLOQ) |
| Reference group | 11.64 (5.57-30.10) | 1.00 | — | 16 (16) |
| ACL injury group | ||||
| Baseline | 8.60 (6.59-12.33) | 0.74 | .175 | 148 (148) |
| 1 y | 8.52 (6.52-12.65) | 0.73 | .135 | 132 (132) |
| 2 y | 7.76 (5.59-10.87) | 0.73 | .042 | 129 (129) |
| Serum IL-10 | Concentration, pg/mL | Norm | P Value | N (n With Data > LLOQ) |
| Reference group | 0.26 (0.13-0.72) | 1.00 | — | 16 (16) |
| ACL injury group | ||||
| Baseline | 0.23 (0.17-0.45) | 0.88 | .731 | 148 (140) |
| 1 y | 0.23 (0.14-0.34) | 0.88 | .333 | 132 (113) |
| 2 y | 0.19 (0.14-0.32) | 0.73 | .244 | 129 (118) |
| Serum IL-13 | Concentration, pg/mL | Norm | P Value | N (n With Data > LLOQ) |
| Reference group | 3.41 (1.23-6.11) | 1.00 | — | 16 (12) |
| ACL injury group | ||||
| Baseline | 3.94 (1.95-7.42) | 1.16 | .510 | 148 (112) |
| 1 y | 3.65 (0.93-8.01) | 1.07 | .685 | 132 (95) |
| 2 y | 3.44 (0.93-7.14) | 1.01 | .794 | 129 (94) |
| Serum TNF-α | Concentration, pg/mL | Norm | P Value | N (n With Data > LLOQ) |
| Reference group | 1.14 (1.01-1.60) | 1.00 | — | 16 (16) |
| ACL injury group | ||||
| Baseline | 1.74 (1.24-2.23) | 1.53 | <.001 | 148 (147) |
| 1 y | 1.55 (1.18-1.98) | 1.36 | .010 | 132 (131) |
| 2 y | 1.61 (1.21-2.02) | 1.41 | .005 | 129 (127) |
| Urine NTX-I | Concentration, nmol/mmol Creatinine | Norm | P Value | N (n With Data > LLOQ) |
| Reference group | 45 (33-55) | 1.00 | — | 62 (52) |
| ACL injury group | ||||
| Baseline | 58 (38-83) | 1.29 | <.001 | 150 (149) |
| 1 y | 44 (31-63) | 0.98 | .589 | 140 (139) |
| 2 y | 44 (32-68) | 0.98 | .519 | 136 (133) |
| Urine CTX-II | Concentration, ng/mmol Creatinine | Norm | P Value | N (n With Data > LLOQ) |
| Reference group | 212 (136-437) | 1.00 | — | 62 (52) |
| ACL injury group | ||||
| Baseline | 791 (350-1498) | 3.73 | <.001 | 150 (149) |
| 1 y | 544 (319-1220) | 2.57 | <.001 | 140 (138) |
| 2 y | 526 (262-942) | 2.48 | <.001 | 136 (130) |
a
Data are presented as the median (interquartile range) unless otherwise specified. The Mann-Whitney U test was used for comparisons between the ACL injury and reference groups. P values were unadjusted for multiple testing. Statistical significance between groups is shown in boldface. ACL, anterior cruciate ligament; ARGS-aggrecan, aggrecan ARGS neoepitope; CTX-II, C-terminal cross-linked telopeptide of type II collagen; IFN, interferon; IL, interleukin; LLOQ, lower limit of quantification; NTX-I, N-terminal cross-linked telopeptide of type I collagen; TNF-α, tumor necrosis factor–α.
b
Data from 1 patient were missing because of sample depletion.